Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q2 FY2023 Earnings Presentation
16 slides from Natco Pharma's earnings presentation, Nov 11, 2022
Slide 1: Exchange filing cover letter for Q2 FY23 investor presentation
11th November, 2022 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 52481 Scrip Code: NATCOPHARM Dear Sir Sub: - Q2 FY23 Investor P
Slide 2: Natco Pharma Limited Investor Presentation Q2 FY 2022-23
NATCO PHARMA LIMITED INVESTOR PRESENTATION Q2 FY 2022-23 1
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Key Highlights
KEY HIGHLIGHTS Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW. Strong brand position in domestic pharma segments • Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer • Expa
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Financial Performance(1) (₹ in million) Profitability Margins 22,424 22,247 21,557 20,789 20,224 20,438 43.2% 41.6% 33.5% 34.1% 32.9% 31.0% 31.3% 29.0% 23.4% 22.8% 9,688 9,250 20.5% 17.7% 6,973 6,962 6,900 7,098 6,444 6,405 4,860 4,608 4,409 3,625 8.3% 1,700 FY 2017 FY 2018 F
Slide 6: Key Business Segments
KEY BUSINESS SEGMENTS DOMESTIC FORMULATIONS EXPORT FORMULATIONS SUBSIDIARIES API BUSINESS ▪ Three key business segments: Oncology, ▪ Focused on niche opportunities in the US ▪ Operations in • Strategically important division Specialty Pharma, Cardiology and Brazil, Canada, Singapore, Australia • 44
Slide 7: US Market Focus - Complex Generics & Frontend
US MARKET FOCUS- COMPLEX GENERICS & FRONTEND KEY PRODUCTS IN THE PORTFOLIO (1) Therapeutic Segment / Primary Key Brand Molecule Indication Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the Copaxone Glatiramer Acetate CNS/Multiple
Slide 8: Resilient Domestic Pharma Business
RESILIENT DOMESTIC PHARMA BUSINESS OVERVIEW OF DOMESTIC PHARMA BUSINESS ONCOLOGY Three key business segments: Oncology, Pharma specialty and Cardiology & Diabetology One of the leaders in the sale of branded oncology medicines in India Two decades of strong presence in oncology segment. Focus on ni
Slide 9: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA Strong portfolio with 30+ products including Oncology, cardiovascular and CNS therapies 25 approvals in place Launched Nat-Lenalidomide in the market SUBSIDIARIES REVENUE (₹ IN MILLION) BRAZIL 4,011 Launched Azacitidine in Brazil, second generic in the market Continue t
Slide 10: API Facilities
API FACILITES Strategically important business – develops APIs primarily for third party sales and also for captive consumption MEKAGUDA Portfolio of 44 (1) active US DMFs with niche products under development TELANGANA Oncology API's and speciality Focuses on complex molecules in oncology and CNS s
Slide 11: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS DOMESTIC MARKETS KOTHUR VISAKAPATNAM NAGARJUNASAGAR GUWAHATI DEHRADUN-UNIT VI DEHRADUN UNIT VII TELANGANA ANDHRA PRADESH TELANGANA ASSAM UTTARAKHAND UTTARAKHAND Oral and solid dosages Solid oral tablet and Oncology, Antibiotics Tablets, Capsules Tablets,
Slide 12: R&D Capabilities
R&D CAPABILITIES 2,500 R&D Expense (₹ in million) 14.0% 12% 12.0% R&D capabilities demonstrated by its complex and niche product filings in formulations 2,000 and API segments 9.3% 9.1% 10.0% 8.7% 7.8% 1,500 8.0% 6.2% 2,267 6.0% 1,000 1,976 1,665 1,656 Two research facilities with capabilities acros
Slide 13: Crop Health Sciences
CROP HEALTH SCIENCES Completed state-of-the-art greenfield manufacturing facilities for agro technical and formulation products, with a total Capex spend of over INR 150 crores Targeting two categories of products – bioproducts and pesticides. Launched first pheromone-based mating disruption product
Slide 14: Consolidated Financials
CONSOLIDATED FINANCIALS CONSOLIDATED PROFIT & LOSS STATEMENT (₹ IN MILLION) CONSOLIDATED BALANCE SHEET (₹ IN MILLION) Year ended S.No. Particulars As of 31 March 2022 As of 31 March 2021 31 March 2022 31 March 2021 I Assets Income (1) Non-current assets 1 Revenue from operations 19,448 20,521 (a) Pr
Slide 15: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (₹ IN MILLION) CONSOLIDATED FINANCIAL RESULTS (₹ IN MILLION) Revenue Division Q2FY23 Q2FY22 FY 22 FY21 Q2FY23 Q2FY22 FY22* FY21 A) API Revenue(1):- 441 763 2,481 5,120 Total Revenues 4,526 4,152 20,438 21,557 B) Formulation:- EBITDA 1,158 1,085 3,625 7
Slide 16: Investor Relations Contact
Email: ir@natcopharma.co.in Phone: 040-2354 7532 15